Nanosonics (ASX:NAN) has secured US Food and Drug Administration clearance to launch its trophon3 ultrasound disinfection system alongside a new software upgrade for existing trophon2 users, according to a Wednesday Australian bourse filing.
The trophon3 is set to deliver 40% faster disinfection, enhanced digital integration, and industry-leading traceability with new digital imaging and communications in medicine connectivity (DICOM), the filing said.
The launch will drive growth in hospitals and private practices and upgrade 10,000 original devices, while the trophon2 Plus upgrade targets 20,000 existing users, the filing added.